TY  - JOUR
AU  - Almeida, Jani-Sofia
AU  - Couceiro, Patrícia
AU  - Lopez-Sejas, Nelson
AU  - Alves, Vera
AU  - Růžičkova, Lenka
AU  - Tarazona, Raquel
AU  - Solana, Rafael
AU  - Freitas-Tavares, Paulo
AU  - Santos-Rosa, Manuel
AU  - Rodrigues-Santos, Paulo
PY  - 2019
DO  - 10.3389/fimmu.2019.02493
UR  - http://hdl.handle.net/10668/14649
T2  - Frontiers in immunology
AB  - Therapy with Tyrosine Kinase Inhibitors (TKI) aiming stable deep molecular response is the gold standard to treat Chronic Myeloid Leukemia (CML). NKT-like cells (CD3+CD56+) combine characteristics of T and NK cells. The physiopathological role of...
LA  - en
PB  - Frontiers Research Foundation
KW  - NKT-like cells
KW  - Chronic myeloid leukemia
KW  - Immune checkpoints
KW  - Natural cytotoxicity receptors
KW  - Tyrosine kinase inhibitors
KW  - Antigens, differentiation
KW  - Female
KW  - Gene expression regulation, leukemic
KW  - Humans
KW  - K562 Cells
KW  - Leukemia, myelogenous, chronic, BCR-ABL positive
KW  - Male
KW  - Natural killer T-cells
KW  - Neoplasm proteins
KW  - Protein kinase inhibitors
TI  - NKT-Like (CD3+CD56+) Cells in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.
TY  - research article
VL  - 10
ER  -